X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

Biotechnology

Healthcare
$2.96 +1.49%

+$0.06 today

Market cap
$302.26M
Beta
0.37
P/E (TTM)
-5.2
EPS (TTM)
-$0.79
52W Low $1.35High $4.83

Volume 1.12M

Average 0.40M

Returns on capital

X4 Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-42.5%

avg -12.1%

ROIC

-32.7%

avg -460.5%

ROA

-27.3%

avg -105.3%

Analysis

ROA is currently the strongest return metric at -27.3% versus its period average of -105.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

David H. Kirske

Chief Financial Officer, Treasurer & Corporate SecretaryUSD 722.33K72——

Adam R. Craig

Executive ChairUSD 575.55K60333.25K0.35%

John Volpone

President & Chief Operating OfficerUSD 532.99K51265.31K0.28%

Keith T. Flaherty

Founder & Member of Corporate Advisory Board—55——

Richard Peters

Founder—64——

Renato T. Skerlj

Founder————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 16, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$11,883.64

Sells

5

$462,964.22

Net Transaction Value

−$451,080.58

Net selling

Most Active

KIRSKE DAVID

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 16, 26

Craig Adam R

Direct

Buy$11.9K
Oct 1, 26

KIRSKE DAVID

Direct

Sell$33.7K
Aug 12, 26

Volpone John

Direct

Sell$109.2K
Aug 12, 26

Craig Adam R

Direct

Sell$210.8K
Jun 30, 26

KIRSKE DAVID

Direct

Sell$36.4K
May 12, 26

KIRSKE DAVID

Direct

Sell$72.8K

Summary

Insiders reported 1 buys worth $11,883.64 and 5 sells worth $462,964.22 over the last 12 months. That adds up to net selling of $451,080.58. KIRSKE DAVID was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+71.7% (5yr)2 analysts
Net IncomeN/AN/AN/A
N/A2 analysts
EBITN/AN/AN/A
N/A2 analysts

Analysis

Forward estimates point to Revenue at +71.7% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does X4 Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about XFOR's management, answered from reported figures.

Who manages XFOR?

X4 Pharmaceuticals, Inc. (XFOR) lists 6 active executives. The top listed executive is Adam R. Craig, Executive Chair.

Are XFOR insiders buying or selling?

Recent insider activity shows net buying of $25.18M.